Prognostic value of interim FDG-PET in DLBCL
•
1 like•16 views
- The study evaluated the prognostic value of interim FDG-PET in diffuse large B-cell lymphoma (DLBCL) using data from the CALGB 50303 clinical trial. - It found that change in SUVmax (ΔSUVmax) between baseline and interim PET predicted overall survival, with 2-year survival rates of 68.8% for non-responders vs 93.8% for responders. - Using the Deauville 5-point scale to interpret interim PET results also predicted progression-free and overall survival. However, ΔSUVmax may be a better imaging biomarker to guide clinical trial design using PET response-adapted therapy in DLBCL.
Report
Share
Report
Share
Download to read offline
Recommended
Badakhshi Cancer with oligometastases 2016
This document contains information about cancer from various sources. It discusses the highest causes of cancer mortality being lung cancer, breast cancer, and colorectal cancer. It also discusses treatments for oligometastatic cancer, including stereotactic radiosurgery for brain metastases, surgery or stereotactic ablative radiotherapy for limited lung metastases, and surgery for isolated liver or other organ metastases. The document suggests that an aggressive approach to treating oligometastatic disease may provide a path toward cure for some cancer patients.
The OncoScan(TM) platform for analysis of copy number and somatic mutations i...
The OncoScan microarray offers high-quality copy number, genotype, and somatic mutation data with whole-genome coverage and high resolution in cancer genes for use with challenging FFPE samples.
Solitary cerebral metastasis from undiagnosed prostate cancer. potential role...
Solitary cerebral metastasis from undiagnosed prostate cancer. potential role...Clinical Surgery Research Communications
This document describes a case of a 73-year-old man who presented with neurological symptoms and was found to have a brain lesion that was determined to be a solitary cerebral metastasis. Further investigation did not reveal the primary site. The patient underwent resection of the brain lesion, which was determined to be metastatic prostate cancer based on histopathology. Subsequent multiparametric MRI of the prostate revealed a lesion highly suggestive of prostate cancer. The document argues that multiparametric MRI of the prostate should be included in the diagnostic workup for patients presenting with cerebral metastases of unknown primary, as it may help identify occult prostate primary cancers earlier and guide more targeted treatment.1509 webinar oligometa lung
- Oligometastatic disease refers to a limited number of metastases that may be amenable to local treatment.
- Stereotactic body radiation therapy (SBRT) for lung oligometastases from various primary cancers can achieve high rates of local control with minimal toxicity.
- Patient selection is important, with longer disease-free interval, fewer metastatic sites, and controlled primary tumor associated with improved outcomes after aggressive local therapy of oligometastases.
- Ongoing clinical trials are investigating SBRT for synchronous and metachronous oligometastatic disease to define optimal patient populations and treatment approaches.
Affymetrix OncoScan®* data analysis with Nexus Copy Number™
This document discusses the analysis of Affymetrix OncoScan data using Nexus Copy Number software. It outlines researchers' needs such as visualizing data, identifying common aberrations, comparing sample populations, and predictive analysis. It then describes the data processing in Nexus, including algorithms for identifying significant aberrations and dealing with heterogeneity. Finally, it shows examples of data visualization, analysis features for survival, enrichment, and comparing groups that Nexus provides to help researchers analyze and understand OncoScan data.
Molecular imaging – a new field for a new world By Zaver M. Bhujwalla
Molecular imaging – a new field for a new world By Zaver M. BhujwallaMolecular Imaging Society of India (MISI)
Molecular imaging has revolutionized our perceptions of imaging. This high impact field is finding transformative applications in the understanding, detection, and treatment of nearly all diseases.
The field of molecular imaging is a an exciting fusion and integration of many different disciplines including molecular biology, chemistry and probe design, imaging technologies, visualization, and image analysis, that are focused on understanding, detecting, and treating oncological, neurological, cardiovascular, inflammatory, metabolic, and infectious diseases. Based on their strengths, different imaging modalities provide different but equally valuable information that can be integrated in advancing our understanding of these diseases.
As the era of ‘omics’ progresses towards personalized medicine, the field of molecular imaging is finding multiple uses in noninvasive characterization of the molecular features of diseases and their impact on function. In complex diseases such as cancer, with its tremendous genetic diversity, it is becoming increasingly important to develop molecularly-targeted treatment strategies that combine detection with treatment.Stone Studies- World of EndoUrol
This document summarizes three studies on imaging techniques for renal calculi:
1) A study on a new MRI contrast agent found it was successfully synthesized and showed potential as a contrast agent for bladder cancer detection with in vitro experiments.
2) A study found that contemporary CT radiation exposure for renal colic is only marginally higher than historic IVU techniques, with improved time to diagnosis.
3) A study found digital plain X-rays have good sensitivity for detecting calcium-based kidney stones larger than 5mm, especially in the upper urinary tract, but CT or ultrasound may still be needed for smaller or lower tract stones.
Clinical Genomics for Personalized Cancer Medicine: Recent Advances, Challeng...
I reviewed recent advances, challenges, and opportunities to implement clinical cancer genomics. Case studies of advanced systems, such as Foundation Medicine, MI-ONCOSEQ are introduced for benchmark. A few fundamental limitations to establish personalized oncology are also discussed.
Recommended
Badakhshi Cancer with oligometastases 2016
This document contains information about cancer from various sources. It discusses the highest causes of cancer mortality being lung cancer, breast cancer, and colorectal cancer. It also discusses treatments for oligometastatic cancer, including stereotactic radiosurgery for brain metastases, surgery or stereotactic ablative radiotherapy for limited lung metastases, and surgery for isolated liver or other organ metastases. The document suggests that an aggressive approach to treating oligometastatic disease may provide a path toward cure for some cancer patients.
The OncoScan(TM) platform for analysis of copy number and somatic mutations i...
The OncoScan microarray offers high-quality copy number, genotype, and somatic mutation data with whole-genome coverage and high resolution in cancer genes for use with challenging FFPE samples.
Solitary cerebral metastasis from undiagnosed prostate cancer. potential role...
Solitary cerebral metastasis from undiagnosed prostate cancer. potential role...Clinical Surgery Research Communications
This document describes a case of a 73-year-old man who presented with neurological symptoms and was found to have a brain lesion that was determined to be a solitary cerebral metastasis. Further investigation did not reveal the primary site. The patient underwent resection of the brain lesion, which was determined to be metastatic prostate cancer based on histopathology. Subsequent multiparametric MRI of the prostate revealed a lesion highly suggestive of prostate cancer. The document argues that multiparametric MRI of the prostate should be included in the diagnostic workup for patients presenting with cerebral metastases of unknown primary, as it may help identify occult prostate primary cancers earlier and guide more targeted treatment.1509 webinar oligometa lung
- Oligometastatic disease refers to a limited number of metastases that may be amenable to local treatment.
- Stereotactic body radiation therapy (SBRT) for lung oligometastases from various primary cancers can achieve high rates of local control with minimal toxicity.
- Patient selection is important, with longer disease-free interval, fewer metastatic sites, and controlled primary tumor associated with improved outcomes after aggressive local therapy of oligometastases.
- Ongoing clinical trials are investigating SBRT for synchronous and metachronous oligometastatic disease to define optimal patient populations and treatment approaches.
Affymetrix OncoScan®* data analysis with Nexus Copy Number™
This document discusses the analysis of Affymetrix OncoScan data using Nexus Copy Number software. It outlines researchers' needs such as visualizing data, identifying common aberrations, comparing sample populations, and predictive analysis. It then describes the data processing in Nexus, including algorithms for identifying significant aberrations and dealing with heterogeneity. Finally, it shows examples of data visualization, analysis features for survival, enrichment, and comparing groups that Nexus provides to help researchers analyze and understand OncoScan data.
Molecular imaging – a new field for a new world By Zaver M. Bhujwalla
Molecular imaging – a new field for a new world By Zaver M. BhujwallaMolecular Imaging Society of India (MISI)
Molecular imaging has revolutionized our perceptions of imaging. This high impact field is finding transformative applications in the understanding, detection, and treatment of nearly all diseases.
The field of molecular imaging is a an exciting fusion and integration of many different disciplines including molecular biology, chemistry and probe design, imaging technologies, visualization, and image analysis, that are focused on understanding, detecting, and treating oncological, neurological, cardiovascular, inflammatory, metabolic, and infectious diseases. Based on their strengths, different imaging modalities provide different but equally valuable information that can be integrated in advancing our understanding of these diseases.
As the era of ‘omics’ progresses towards personalized medicine, the field of molecular imaging is finding multiple uses in noninvasive characterization of the molecular features of diseases and their impact on function. In complex diseases such as cancer, with its tremendous genetic diversity, it is becoming increasingly important to develop molecularly-targeted treatment strategies that combine detection with treatment.Stone Studies- World of EndoUrol
This document summarizes three studies on imaging techniques for renal calculi:
1) A study on a new MRI contrast agent found it was successfully synthesized and showed potential as a contrast agent for bladder cancer detection with in vitro experiments.
2) A study found that contemporary CT radiation exposure for renal colic is only marginally higher than historic IVU techniques, with improved time to diagnosis.
3) A study found digital plain X-rays have good sensitivity for detecting calcium-based kidney stones larger than 5mm, especially in the upper urinary tract, but CT or ultrasound may still be needed for smaller or lower tract stones.
Clinical Genomics for Personalized Cancer Medicine: Recent Advances, Challeng...
I reviewed recent advances, challenges, and opportunities to implement clinical cancer genomics. Case studies of advanced systems, such as Foundation Medicine, MI-ONCOSEQ are introduced for benchmark. A few fundamental limitations to establish personalized oncology are also discussed.
Utsw 2020 1
I. The document discusses developing a framework for individualizing radiation dose based on genetic and imaging data from tumor samples. Experimental and clinical studies have been conducted to understand how genetic variants affect radiation sensitivity.
II. Multi-omic databases have been created from analyzing over 1000 cancer cell lines and patient-derived xenografts. Computational and experimental pipelines were used to test over 500 genetic variants across 92 genes to identify variants that regulate survival after radiation.
III. The findings show the potential to associate genetic alterations with radiomic features to help personalize radiation treatment doses for individual patients. Further work is still needed to fully validate new genetic variants and their molecular mechanisms of radiation sensitivity.
Sequencing 60,000 Samples: An Innovative Large Cohort Study for Breast Cancer...
This slidedeck focuses on the design of a large cohort study for assessing breast cancer risk and how an innovative digital sequencing approach is able to solve the previously unmet challenges of this type of NGS study design. Our speaker, Dr. Fergus J. Couch of the Mayo Clinic, presents on the design of this NCI-funded project, which comprises the sequencing of 60,000 samples to assess the risk of breast cancer through association with targeted genes. The design and size of the study requires an accurate, robust and high-throughput sequencing method. The investigators are using a digital DNA sequencing approach from QIAGEN that incorporates molecular barcodes to tag and remove PCR duplicates and increase NGS assay sensitivity. The approach also uses proprietary chemistry that enables uniform sequencing to efficiently utilize sequencing power and deliver optimized results.
BALKAN MCO 2011 - J. Vermorken - Head and neck cancer - essential messages
BALKAN MCO 2011 - J. Vermorken - Head and neck cancer - essential messages European School of Oncology
Head and neck cancer accounts for 5-6% of all cancers, with over 90% being squamous cell carcinomas. Risk factors include tobacco, alcohol, and HPV. Treatment options include surgery, radiation therapy, chemotherapy, or combinations. While early stage cancer has a good prognosis with single modality treatment, advanced stages generally require combined modality treatment, though 5-year survival remains below 35%. New targeted therapies and improved radiation techniques have provided benefits in recent years.Cetuximab in scchn how far we go?
Overview of the role of bio-radiation in the management of locally advanced head and neck squamous cell carcinoma.
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
1) The document discusses targeted therapies for non-small cell lung cancer (NSCLC) with ALK translocations, including crizotinib, alectinib, brigatinib, ceritinib, and lorlatinib.
2) Alectinib is now considered the preferred first-line treatment for ALK-positive NSCLC based on Phase III trials showing it is more effective than crizotinib.
3) For patients who progress on a first-generation ALK inhibitor like crizotinib, later-generation ALK inhibitors such as ceritinib, brigatinib, and lorlatinib have demonstrated efficacy in clinical trials as subsequent therapies.
Cetuximab Plus Radiotherapy For Head And Neck Cancer
1) The document discusses a randomized controlled trial comparing radiotherapy alone versus radiotherapy plus cetuximab for locally advanced squamous cell carcinoma of the head and neck.
2) The trial found that adding cetuximab to radiotherapy improved locoregional control and overall survival compared to radiotherapy alone, with a 13% reduction in risk of locoregional recurrence and 11% reduction in risk of death.
3) Toxicities were similar between the two groups except patients receiving cetuximab experienced more rash, with 13 patients discontinuing due to rash or hypersensitivity reactions.
MCO 2011 - Slide 27 - R.A. Stahel - NSCLC systemic therapy
This document summarizes the evolution of systemic therapy for non-small cell lung cancer (NSCLC) from empiric chemotherapy to molecularly-driven approaches. It discusses:
1) How histological classification is now necessary for treatment decisions, as different chemotherapy regimens have different efficacy depending on adenocarcinoma or squamous cell carcinoma subtype.
2) How maintenance therapy and extended duration of therapy have shown survival benefits compared to stopping treatment after a set number of cycles.
3) The need for molecular classification of NSCLC to guide targeted therapies, including determining EGFR and ALK status to select appropriate first-line tyrosine kinase inhibitors or chemotherapy. Ongoing research aims to identify more driver mutations
MET Crusader TKI presentation
Panel discussion by top clinicians and researchers on the effectiveness of Tyrosine Kinase Inhibitors (TKI) on cancer
Circulating Cell Free DNA Targeted Sequencing Workflow | ESHG 2015 Poster PM1...
Circulating Cell Free DNA Targeted Sequencing Workflow | ESHG 2015 Poster PM1...Thermo Fisher Scientific
Circulating cell free DNA is a potential tumor marker in a non-invasive blood test for the treatment and evaluation of cancer and recurrence monitoring. As circulating tumor DNA is often present at low frequencies within circulating cell free DNA, targeted sequencing on the Ion Torrent™ platform is an optimal tool or mutation detection with very little sample input required. Here, we demonstrate a complete workflow from isolation through molecular characterization of circulating tumor DNA. We have optimized a protocol using magnetic beads to isolate circulating cell free DNA. This protocol is easily automated to process up to 192 samples a day. It is also easily scalable for any input volume and can elute in volumes down to 15 μL resulting in no loss of low frequency alleles. We demonstrate comparable performance between this bead based isolation and column based isolation. We have completed molecular characterization of circulating cell free DNA using the multiplexing capabilities of AmpliSeq™ and the Ion PGM™. With the Ion AmpliSeq™ Cancer Hotspot Panel v2, we performed targeted sequencing of 50 genes of interest, covering 2800 COSMIC mutations. We demonstrate good reproducibility of amplicon representation as well as allelic frequencies. Through saturation studies and subsampling, we have determined the limit of detection of hotspots circulating cell free DNA on the Ion PGM™ to be below 1%. We further demonstrate proof of principle of this workflow on circulating cell free DNA and matched FFPE samples. Our results verify the accuracy and ease of our workflow. This protocol, from isolation through targeted sequencing, will not only result in a simple sample preparation for circulating cell free DNA but also facilitate rapid mutation detection to advance cancer research.Genes and Tissue Culture Technology - Next Generation Sequencing - Applicatio...
A short presentation on the applications of next generation sequencing in cancer treatment. All content displayed and shared remains the courtesy of Taylor's University. Published 17/10/18.
Alpha auger emitters
Beta and alpha emitters are commonly used radiopharmaceuticals in nuclear medicine therapy. Beta emitters can cause more side effects due to their longer range and lower linear energy transfer compared to alpha emitters. Ra-223 is an alpha-emitting radiopharmaceutical used to treat castration-resistant prostate cancer with bone metastases. It localizes to bone sites and delivers a high dose of radiation to bone tumors while sparing bone marrow due to the short range of alpha particles. Clinical trials have shown Ra-223 improves survival compared to placebo in patients who do not respond to docetaxel.
Oligometastasis
This document summarizes a panel discussion on oligometastatic disease. It defines oligometastatic disease as having a solitary or few detectable metastatic lesions confined to a single organ or more than one organ. There is ongoing debate around how many lesions constitute oligometastatic disease. The document discusses various theories on metastasis patterns and improving treatments like stereotactic radiosurgery that have led to reclassification of some metastatic tumors as oligometastatic. Ongoing trials are exploring more aggressive local treatment of oligometastatic lesions combined with systemic therapies to improve long-term survival.
Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest ...
Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest ...PVI, PeerView Institute for Medical Education
David R. Jones, MD, and Roy S. Herbst, MD, PhD, prepared useful practice aids pertaining to lung cancer for this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2PSVELG. CME credit will be available until November 9, 2021.Webinar - Imaging technologies to visualise drug discovery
Imaging allows a non-invasive assessment of biochemical and biological processes in a living subject. Monitoring, assessing, and characterising novel therapeutics in pre-clinical models is an essential part of drug development.
In this webinar Dr Juliana Maynard, Lead Scientist in Pre-clinical Imaging, and Dr Philippa Hart, Lead Scientist in Mass Spectrometry Imaging, explore available imaging technologies and techniques and explain how they can help at different stages of the drug development process.
The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a...
Epithelial ovarian cancer is the fifth leading cause of cancer-related deaths of women in the United States and Europe and ranks as the second most common type of gynecological malignancy. Most cases are diagnosed in advanced stages and although the response rates to platinum-based chemotherapy are high, the majority of patients nevertheless have poor survival rates. Although the reasons for these poor outcomes are likely to be multifactorial, one particular area of interest has recently focused on hematogenous tumor cell dissemination that has been shown to originate from disseminated tumor cells (DTCs) in the bone marrow (BM) and circulating tumor cells (CTCs) in the blood. Here, we demonstrate that the negative prognostic impact of CTCs and DTCs arise from specific cellular phenotypes and are associated with platinum-resistance and stem cell-associated proteins.
EGFR in cervical cancer
This document summarizes research on evaluating EGFR status in cervical cancer. It finds that EGFR is overexpressed in 92% of cervical cancer tumor cells. Patients with high EGFR expression levels showed poorer response to radiation therapy. The document discusses several studies investigating the use of EGFR inhibitors like cetuximab and erlotinib in combination with chemotherapy and radiation for cervical cancer treatment. Preliminary results suggest these combinations may improve response rates and survival outcomes compared to chemotherapy and radiation alone, but further research is still needed.
Integration Of Targeted Therapies With Radiation Lung Cancer
1) The document discusses integrating targeted therapies such as EGFR inhibitors and angiogenesis inhibitors with chemoradiotherapy for the treatment of stage III non-small cell lung cancer (NSCLC).
2) Several phase II trials showed that combining chemoradiotherapy with the EGFR inhibitor cetuximab was feasible and resulted in promising survival outcomes. This warrants a phase III trial.
3) Combining chemoradiotherapy with tyrosine kinase inhibitors and angiogenesis inhibitors like bevacizumab is also being explored, but data is still limited and complex trial designs make results difficult to interpret. Further research is still needed.
Molecular Imaging
A dynamic look at the current research done in Molecular imaging with different applications of ImmunoPET in medicine.
NGS in cancer treatment
Next generation sequencing (NGS) has various applications in cancer treatment and research. It can be used to identify novel cancer mutations, detect hereditary cancer syndromes, enable personalized cancer treatment based on a patient's genetic profile, and detect circulating tumor DNA (ctDNA). NGS allows comprehensive analysis of cancer genomes and biomarkers for molecular diagnosis, prognosis, and monitoring treatment response. Challenges include analyzing large amounts of NGS data and accurately interpreting genetic variations, but its clinical utility continues to advance personalized cancer care.
BLADDER CANCER - What has changed.pptx
There have been several advances in the treatment of bladder cancer over the past 5 years. Artificial intelligence using convolutional neural networks has shown promise in detecting bladder tumors with high sensitivity and specificity, but overdiagnosis remains a problem. Immunotherapy drugs like pembrolizumab, atezolumab, nivolumab, and enfortumab have been approved for various stages of bladder cancer. Neoadjuvant combinations of chemotherapy and immunotherapy are achieving high rates of pathological complete response. Several targeted therapies including erdafitinib, sacituzumab govitecan, and interleukin-15 analogues are also under investigation.
Advances in Lung Cancer Diagnosis.pptx
Newer advances in diagnosis of Lung Cancer biomarkers provide a more comprehensive perspective. Molecular pathology now supplements traditional histologic classification, with biomarkers like EGFR, ALK, ROS1, and PD-L1 expression level guiding targeted therapy selection. Biomarker testing is important for identifying actionable mutations to help select appropriate targeted therapies and improve patient outcomes. However, barriers remain like insufficient tissue samples, long turnaround times, and lack of universal testing. Efforts are ongoing to address disparities and expand the use of liquid biopsy and next-generation sequencing to overcome challenges and improve personalized treatment of lung cancer.
management of advanced cervical cancer [Autosaved].pptx
The document summarizes current management strategies for locally advanced and metastatic cervical cancer. It discusses the following key points in 3 sentences:
Concurrent chemoradiation (CCRT) with cisplatin is considered the standard treatment for locally advanced cervical cancer (LACC). Studies have shown CCRT provides a 5-year survival advantage of 10-15% compared to radiation alone by reducing local recurrence and improving disease-free survival. Trials have investigated strategies like neoadjuvant chemotherapy (NACT) and extended field radiation but have yielded varying results with no clear consensus on improved outcomes compared to CCRT.
More Related Content
What's hot
Utsw 2020 1
I. The document discusses developing a framework for individualizing radiation dose based on genetic and imaging data from tumor samples. Experimental and clinical studies have been conducted to understand how genetic variants affect radiation sensitivity.
II. Multi-omic databases have been created from analyzing over 1000 cancer cell lines and patient-derived xenografts. Computational and experimental pipelines were used to test over 500 genetic variants across 92 genes to identify variants that regulate survival after radiation.
III. The findings show the potential to associate genetic alterations with radiomic features to help personalize radiation treatment doses for individual patients. Further work is still needed to fully validate new genetic variants and their molecular mechanisms of radiation sensitivity.
Sequencing 60,000 Samples: An Innovative Large Cohort Study for Breast Cancer...
This slidedeck focuses on the design of a large cohort study for assessing breast cancer risk and how an innovative digital sequencing approach is able to solve the previously unmet challenges of this type of NGS study design. Our speaker, Dr. Fergus J. Couch of the Mayo Clinic, presents on the design of this NCI-funded project, which comprises the sequencing of 60,000 samples to assess the risk of breast cancer through association with targeted genes. The design and size of the study requires an accurate, robust and high-throughput sequencing method. The investigators are using a digital DNA sequencing approach from QIAGEN that incorporates molecular barcodes to tag and remove PCR duplicates and increase NGS assay sensitivity. The approach also uses proprietary chemistry that enables uniform sequencing to efficiently utilize sequencing power and deliver optimized results.
BALKAN MCO 2011 - J. Vermorken - Head and neck cancer - essential messages
BALKAN MCO 2011 - J. Vermorken - Head and neck cancer - essential messages European School of Oncology
Head and neck cancer accounts for 5-6% of all cancers, with over 90% being squamous cell carcinomas. Risk factors include tobacco, alcohol, and HPV. Treatment options include surgery, radiation therapy, chemotherapy, or combinations. While early stage cancer has a good prognosis with single modality treatment, advanced stages generally require combined modality treatment, though 5-year survival remains below 35%. New targeted therapies and improved radiation techniques have provided benefits in recent years.Cetuximab in scchn how far we go?
Overview of the role of bio-radiation in the management of locally advanced head and neck squamous cell carcinoma.
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
1) The document discusses targeted therapies for non-small cell lung cancer (NSCLC) with ALK translocations, including crizotinib, alectinib, brigatinib, ceritinib, and lorlatinib.
2) Alectinib is now considered the preferred first-line treatment for ALK-positive NSCLC based on Phase III trials showing it is more effective than crizotinib.
3) For patients who progress on a first-generation ALK inhibitor like crizotinib, later-generation ALK inhibitors such as ceritinib, brigatinib, and lorlatinib have demonstrated efficacy in clinical trials as subsequent therapies.
Cetuximab Plus Radiotherapy For Head And Neck Cancer
1) The document discusses a randomized controlled trial comparing radiotherapy alone versus radiotherapy plus cetuximab for locally advanced squamous cell carcinoma of the head and neck.
2) The trial found that adding cetuximab to radiotherapy improved locoregional control and overall survival compared to radiotherapy alone, with a 13% reduction in risk of locoregional recurrence and 11% reduction in risk of death.
3) Toxicities were similar between the two groups except patients receiving cetuximab experienced more rash, with 13 patients discontinuing due to rash or hypersensitivity reactions.
MCO 2011 - Slide 27 - R.A. Stahel - NSCLC systemic therapy
This document summarizes the evolution of systemic therapy for non-small cell lung cancer (NSCLC) from empiric chemotherapy to molecularly-driven approaches. It discusses:
1) How histological classification is now necessary for treatment decisions, as different chemotherapy regimens have different efficacy depending on adenocarcinoma or squamous cell carcinoma subtype.
2) How maintenance therapy and extended duration of therapy have shown survival benefits compared to stopping treatment after a set number of cycles.
3) The need for molecular classification of NSCLC to guide targeted therapies, including determining EGFR and ALK status to select appropriate first-line tyrosine kinase inhibitors or chemotherapy. Ongoing research aims to identify more driver mutations
MET Crusader TKI presentation
Panel discussion by top clinicians and researchers on the effectiveness of Tyrosine Kinase Inhibitors (TKI) on cancer
Circulating Cell Free DNA Targeted Sequencing Workflow | ESHG 2015 Poster PM1...
Circulating Cell Free DNA Targeted Sequencing Workflow | ESHG 2015 Poster PM1...Thermo Fisher Scientific
Circulating cell free DNA is a potential tumor marker in a non-invasive blood test for the treatment and evaluation of cancer and recurrence monitoring. As circulating tumor DNA is often present at low frequencies within circulating cell free DNA, targeted sequencing on the Ion Torrent™ platform is an optimal tool or mutation detection with very little sample input required. Here, we demonstrate a complete workflow from isolation through molecular characterization of circulating tumor DNA. We have optimized a protocol using magnetic beads to isolate circulating cell free DNA. This protocol is easily automated to process up to 192 samples a day. It is also easily scalable for any input volume and can elute in volumes down to 15 μL resulting in no loss of low frequency alleles. We demonstrate comparable performance between this bead based isolation and column based isolation. We have completed molecular characterization of circulating cell free DNA using the multiplexing capabilities of AmpliSeq™ and the Ion PGM™. With the Ion AmpliSeq™ Cancer Hotspot Panel v2, we performed targeted sequencing of 50 genes of interest, covering 2800 COSMIC mutations. We demonstrate good reproducibility of amplicon representation as well as allelic frequencies. Through saturation studies and subsampling, we have determined the limit of detection of hotspots circulating cell free DNA on the Ion PGM™ to be below 1%. We further demonstrate proof of principle of this workflow on circulating cell free DNA and matched FFPE samples. Our results verify the accuracy and ease of our workflow. This protocol, from isolation through targeted sequencing, will not only result in a simple sample preparation for circulating cell free DNA but also facilitate rapid mutation detection to advance cancer research.Genes and Tissue Culture Technology - Next Generation Sequencing - Applicatio...
A short presentation on the applications of next generation sequencing in cancer treatment. All content displayed and shared remains the courtesy of Taylor's University. Published 17/10/18.
Alpha auger emitters
Beta and alpha emitters are commonly used radiopharmaceuticals in nuclear medicine therapy. Beta emitters can cause more side effects due to their longer range and lower linear energy transfer compared to alpha emitters. Ra-223 is an alpha-emitting radiopharmaceutical used to treat castration-resistant prostate cancer with bone metastases. It localizes to bone sites and delivers a high dose of radiation to bone tumors while sparing bone marrow due to the short range of alpha particles. Clinical trials have shown Ra-223 improves survival compared to placebo in patients who do not respond to docetaxel.
Oligometastasis
This document summarizes a panel discussion on oligometastatic disease. It defines oligometastatic disease as having a solitary or few detectable metastatic lesions confined to a single organ or more than one organ. There is ongoing debate around how many lesions constitute oligometastatic disease. The document discusses various theories on metastasis patterns and improving treatments like stereotactic radiosurgery that have led to reclassification of some metastatic tumors as oligometastatic. Ongoing trials are exploring more aggressive local treatment of oligometastatic lesions combined with systemic therapies to improve long-term survival.
Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest ...
Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest ...PVI, PeerView Institute for Medical Education
David R. Jones, MD, and Roy S. Herbst, MD, PhD, prepared useful practice aids pertaining to lung cancer for this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/2PSVELG. CME credit will be available until November 9, 2021.Webinar - Imaging technologies to visualise drug discovery
Imaging allows a non-invasive assessment of biochemical and biological processes in a living subject. Monitoring, assessing, and characterising novel therapeutics in pre-clinical models is an essential part of drug development.
In this webinar Dr Juliana Maynard, Lead Scientist in Pre-clinical Imaging, and Dr Philippa Hart, Lead Scientist in Mass Spectrometry Imaging, explore available imaging technologies and techniques and explain how they can help at different stages of the drug development process.
The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a...
Epithelial ovarian cancer is the fifth leading cause of cancer-related deaths of women in the United States and Europe and ranks as the second most common type of gynecological malignancy. Most cases are diagnosed in advanced stages and although the response rates to platinum-based chemotherapy are high, the majority of patients nevertheless have poor survival rates. Although the reasons for these poor outcomes are likely to be multifactorial, one particular area of interest has recently focused on hematogenous tumor cell dissemination that has been shown to originate from disseminated tumor cells (DTCs) in the bone marrow (BM) and circulating tumor cells (CTCs) in the blood. Here, we demonstrate that the negative prognostic impact of CTCs and DTCs arise from specific cellular phenotypes and are associated with platinum-resistance and stem cell-associated proteins.
EGFR in cervical cancer
This document summarizes research on evaluating EGFR status in cervical cancer. It finds that EGFR is overexpressed in 92% of cervical cancer tumor cells. Patients with high EGFR expression levels showed poorer response to radiation therapy. The document discusses several studies investigating the use of EGFR inhibitors like cetuximab and erlotinib in combination with chemotherapy and radiation for cervical cancer treatment. Preliminary results suggest these combinations may improve response rates and survival outcomes compared to chemotherapy and radiation alone, but further research is still needed.
Integration Of Targeted Therapies With Radiation Lung Cancer
1) The document discusses integrating targeted therapies such as EGFR inhibitors and angiogenesis inhibitors with chemoradiotherapy for the treatment of stage III non-small cell lung cancer (NSCLC).
2) Several phase II trials showed that combining chemoradiotherapy with the EGFR inhibitor cetuximab was feasible and resulted in promising survival outcomes. This warrants a phase III trial.
3) Combining chemoradiotherapy with tyrosine kinase inhibitors and angiogenesis inhibitors like bevacizumab is also being explored, but data is still limited and complex trial designs make results difficult to interpret. Further research is still needed.
Molecular Imaging
A dynamic look at the current research done in Molecular imaging with different applications of ImmunoPET in medicine.
NGS in cancer treatment
Next generation sequencing (NGS) has various applications in cancer treatment and research. It can be used to identify novel cancer mutations, detect hereditary cancer syndromes, enable personalized cancer treatment based on a patient's genetic profile, and detect circulating tumor DNA (ctDNA). NGS allows comprehensive analysis of cancer genomes and biomarkers for molecular diagnosis, prognosis, and monitoring treatment response. Challenges include analyzing large amounts of NGS data and accurately interpreting genetic variations, but its clinical utility continues to advance personalized cancer care.
What's hot (19)
Sequencing 60,000 Samples: An Innovative Large Cohort Study for Breast Cancer...
Sequencing 60,000 Samples: An Innovative Large Cohort Study for Breast Cancer...
BALKAN MCO 2011 - J. Vermorken - Head and neck cancer - essential messages
BALKAN MCO 2011 - J. Vermorken - Head and neck cancer - essential messages
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
Role of Chemotherapy, Targeted therapy and Immunotherapy in NSCLC (Part II)
Cetuximab Plus Radiotherapy For Head And Neck Cancer
Cetuximab Plus Radiotherapy For Head And Neck Cancer
MCO 2011 - Slide 27 - R.A. Stahel - NSCLC systemic therapy
MCO 2011 - Slide 27 - R.A. Stahel - NSCLC systemic therapy
Circulating Cell Free DNA Targeted Sequencing Workflow | ESHG 2015 Poster PM1...
Circulating Cell Free DNA Targeted Sequencing Workflow | ESHG 2015 Poster PM1...
Genes and Tissue Culture Technology - Next Generation Sequencing - Applicatio...
Genes and Tissue Culture Technology - Next Generation Sequencing - Applicatio...
Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest ...
Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest ...
Webinar - Imaging technologies to visualise drug discovery
Webinar - Imaging technologies to visualise drug discovery
The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a...
The Presence and Persistence of Resistant and Stem Cell-Like Tumor Cells as a...
Integration Of Targeted Therapies With Radiation Lung Cancer
Integration Of Targeted Therapies With Radiation Lung Cancer
Similar to Prognostic value of interim FDG-PET in DLBCL
BLADDER CANCER - What has changed.pptx
There have been several advances in the treatment of bladder cancer over the past 5 years. Artificial intelligence using convolutional neural networks has shown promise in detecting bladder tumors with high sensitivity and specificity, but overdiagnosis remains a problem. Immunotherapy drugs like pembrolizumab, atezolumab, nivolumab, and enfortumab have been approved for various stages of bladder cancer. Neoadjuvant combinations of chemotherapy and immunotherapy are achieving high rates of pathological complete response. Several targeted therapies including erdafitinib, sacituzumab govitecan, and interleukin-15 analogues are also under investigation.
Advances in Lung Cancer Diagnosis.pptx
Newer advances in diagnosis of Lung Cancer biomarkers provide a more comprehensive perspective. Molecular pathology now supplements traditional histologic classification, with biomarkers like EGFR, ALK, ROS1, and PD-L1 expression level guiding targeted therapy selection. Biomarker testing is important for identifying actionable mutations to help select appropriate targeted therapies and improve patient outcomes. However, barriers remain like insufficient tissue samples, long turnaround times, and lack of universal testing. Efforts are ongoing to address disparities and expand the use of liquid biopsy and next-generation sequencing to overcome challenges and improve personalized treatment of lung cancer.
management of advanced cervical cancer [Autosaved].pptx
The document summarizes current management strategies for locally advanced and metastatic cervical cancer. It discusses the following key points in 3 sentences:
Concurrent chemoradiation (CCRT) with cisplatin is considered the standard treatment for locally advanced cervical cancer (LACC). Studies have shown CCRT provides a 5-year survival advantage of 10-15% compared to radiation alone by reducing local recurrence and improving disease-free survival. Trials have investigated strategies like neoadjuvant chemotherapy (NACT) and extended field radiation but have yielded varying results with no clear consensus on improved outcomes compared to CCRT.
2009 PET Review And NOPR Update
This document summarizes the findings of a large study conducted by the National Cancer Center Network (NCCN) and National Oncologic PET Registry (NOPR) on the impact of positron emission tomography (PET) on cancer management. The study analyzed over 130,000 patient scans from 1,891 PET facilities. It found that in 38% of cases, PET led to a change in the referring physician's intended patient management approach, such as changing or adjusting therapy. The study demonstrates the utility of PET in cancer evaluation and treatment decision making.
E-book Thesis Sara Carvalho
This chapter discusses rapid learning health care as an approach to enable customized radiotherapy. It describes a 4-phase methodology: 1) collecting diverse patient, treatment and outcome data, 2) developing prediction models using machine learning to analyze the data, 3) applying the models in clinical practice via decision support systems, and 4) evaluating predicted vs actual outcomes. The goal is to improve treatment predictability and ensure patients receive optimal therapy while efficiently using resources. Next steps involve including patient preferences in decision making for personalized cancer care.
MON 2011 - Slide 24 - R.A. Stahel - NSCLC systemic therapy
This document summarizes the evolution of systemic therapy for non-small cell lung cancer (NSCLC) from empiric chemotherapy to molecularly-driven approaches. It discusses:
1) How histological classification is now necessary for treatment decisions, as different chemotherapy regimens have different efficacy depending on adenocarcinoma or squamous cell carcinoma subtype.
2) How maintenance therapy and extended duration of therapy have shown survival benefits compared to stopping treatment after a set number of cycles.
3) The need for molecular classification of NSCLC to guide targeted therapies, including determining EGFR and ALK status to select appropriate first-line tyrosine kinase inhibitors or chemotherapy. Ongoing research aims to identify more driver mutations
Advances in oncological PET/CT Imaging
This document discusses advances in oncological PET imaging. It begins by outlining limitations of current PET/CT imaging related to false positives, false negatives, and radiation exposure. It then describes several advances in PET imaging including new radiotracers for tumor characterization, instrumentation improvements, software enhancements to reduce radiation dose, and hybrid PET/MRI imaging. The document provides examples of how various new radiotracers beyond FDG can provide clinical benefits for tumor imaging and characterization.
Precision Radiotherapy: Tailoring Treatment for Individualised Cancer Care.pptx
Precision radiotherapy, also known as precision radiation therapy or targeted radiotherapy, is a cutting-edge approach in the field of radiation oncology that aims to deliver highly focused and accurate doses of radiation to cancerous cells while minimizing damage to surrounding healthy tissues.
Oligometastatic prostate cancer- radiation Therapy
The document discusses the role of radiation therapy in treating oligometastatic prostate cancer, noting that radiation can potentially achieve durable responses or even cure in some cases when metastases are limited. It reviews definitions of oligometastatic prostate cancer, the rationale for local and metastasis-directed radiation therapy, clinical evidence from studies on the use of external beam radiation therapy and stereotactic body radiation therapy to treat the primary tumor and metastases, and outcomes from these studies including local control rates, progression-free survival, and overall survival. The document concludes that radiation therapy plays an important role in the treatment of oligometastatic prostate cancer.
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...Scintica Instrumentation
Learning Objectives:
Understand convection-enhanced delivery and its implication for brain tumour treatment
Understand how gold nanoparticles can be used to construct radiation nanomedicine
Learn how to evaluate the safety, toxicity, and effectiveness of radiation nanomedicines
Overview:
Glioblastoma is a devastatingly aggressive type of brain tumour with a low median, and 5-year survival that has lacked new treatment options, in part due to the inability of therapeutic agents to cross the blood-brain barrier. Convection Enhanced Delivery (CED), a clinical neurosurgical strategy has been used to locoregionally deliver various therapeutic agents within the brain. Radiotherapeutic agents, such as 177Lu-labeled gold nanoparticles (177Lu-AuNP), hold promise for treatment of glioblastoma when administered by CED. Intratumoural injections of 177Lu-AuNP administered by CED was evaluated in an orthotopic xenograft mouse model of glioblastoma. SPECT/CT and biodistribution studies were used to evaluate the fate of the 177Lu-AuNP after injection. These results were used to estimate organ radiation absorbed doses. Normal tissue toxicity was evaluated to confirm the safety of the injections. Magnetic resonance imaging and bioluminescence imaging were used to monitor tumour growth after administration of 177Lu-AuNP, and median survival was estimated.Role of Radiation Therapy for Lung Cancer
Radiation therapy plays an evolving role in the treatment of lung cancer beyond just causing DNA double strand breaks.
1) Stereotactic body radiation therapy (SBRT) can provide curative treatment for early stage lung cancer with high local control rates.
2) For locally advanced lung cancer, dose escalation with conventional fractionation in RTOG 0617 did not improve overall survival, highlighting the importance of fractionation and sequencing with other therapies.
3) Radiation induces tumor cell death that can elicit anti-tumor immune responses, known as abscopal effects, especially when combined with immunotherapy like anti-CTLA4 and anti-PD1/PDL1 agents which play complementary roles.
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...European School of Oncology
1. The document discusses various clinical and pathological factors that can help predict outcomes for prostate cancer patients undergoing surgery, such as cancer volume, Gleason grade, clinical stage, and PSA levels.
2. Nomograms and statistical models have been developed using these factors to predict chances of cancer recurrence, pathologic stage, and disease progression.
3. However, some factors like clinical stage may have limited predictive value. Ongoing research aims to improve predictive accuracy by addressing issues like PSA standardization and biopsy upgrading.INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
Durvalumab plus chemotherapy significantly improved overall survival versus placebo plus chemotherapy in the Phase III TOPAZ-1 trial of previously untreated advanced biliary tract cancer. Median overall survival was 12.8 months with durvalumab and gemcitabine/cisplatin versus 11.6 months with gemcitabine/cisplatin alone. Progression-free survival and objective response rate were also improved with the addition of durvalumab. Safety profiles were similar between the groups. Pembrolizumab plus gemcitabine and cisplatin also significantly improved overall survival compared to gemcitabine and cisplatin alone in the Phase III KEYNOTE-966 trial of previously untreated advanced biliary tract cancer.
Biomarkers in head and neck cancers final ajeet
This document provides an overview of biomarkers in head and neck cancers. It discusses how biomarkers can be used for early diagnosis, predicting response to therapy, and identifying therapeutic targets. Key points include:
- Biomarkers like HPV status, ERCC1, and beta-tubulin isoform III may help predict response to chemotherapy and radiation. HPV+ tumors have a better prognosis.
- The EGFR pathway is commonly dysregulated in head and neck cancers but targeting it has had limited success due to resistance mechanisms. EGFRvIII mutations may reduce sensitivity to cetuximab.
- Ongoing research explores using biomarkers to guide more personalized treatment, such as reducing therapy for HPV+ tumors or targeting pathways
USE OF PET – HEALTH CARE POLICY PERSPECTIVES
POSITRON EMISSION TOMOGRAPHY (PET) USE BY TERTIARY HEALTH CARE CENT RES AND ITS ACCESSIBILITY TO POPULATION: A POLICY PERSPECTIVE. a BRIEF Cost-Benefit analysis.
SBRT in head and neck cancer
This document discusses stereotactic body radiation therapy (SBRT) for head and neck cancers. It provides an overview of SBRT indications, efficacy, toxicity profiles, quality of life outcomes, fractionation schedules, target definition, constraints, and the role of cetuximab. Several studies on SBRT for recurrent head and neck cancers, primary cancers metastatic to the head and neck region, and target volume delineation are summarized. Toxicities are generally low but carotid blowout syndrome remains a concern, especially for tumors adjacent to carotid arteries.
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Ponencia en el VII Congreso internacional de coloproctología, Bogotá, 18.08.2016. Con énfasis en los estudios recientes en terapia antiangiogénica, y el impacto del lado del primario en el pronóstico (y aspectos predictivos) de la enfermedad metastásica.
G. Ceresoli - Lung cancer - State of the art
The document summarizes information about lung cancer, including:
1) Lung cancer subtypes are small cell carcinoma (13%), large cell carcinoma (5%), adenocarcinoma (38.3%), and squamous cell carcinoma (19.7%).
2) Adjuvant chemotherapy in resected early-stage non-small cell lung cancer (NSCC) improves survival compared to surgery alone, though benefits vary by stage. Platinum-based regimens like cisplatin and vinorelbine are commonly used.
3) For locally advanced unresectable NSCLC, concurrent chemoradiotherapy is superior to sequential chemotherapy and radiotherapy, improving median and 5-year survival.
Perspective: Imaging for Gliomas
The 2016 World Health Organization classification of tumors of the central nervous system broadly employs genetic alterations for diagnostic criteria including isocitrate dehydrogenase-1 (IDH1) mutation or IDH2 mutation, and 1p/19q codeletion,[1] with the goal of creating more homogeneous disease categories with greater prognostic value.[2-5] Molecular diagnostics is becoming an increasingly important aspect of clinical oncologic neuropathology practice.
Kshivets O. Local Advanced Lung Cancer Surgery
The document summarizes research on optimal surgery strategies for patients with local advanced lung cancer. The study analyzed 155 patients who underwent radical combined procedures. Key findings include:
1) Adjuvant chemoimmunoradiotherapy after surgery significantly improved 5-year survival compared to surgery alone or postoperative radiotherapy alone.
2) Factors associated with improved 5-year survival in multivariate analysis included nodal stage, adjuvant therapy, gender, blood markers, and cell ratios.
3) Neural network modeling accurately predicted 5-year survival based on clinicopathological factors, with nodal stage and adjuvant therapy being the top predictors.
Similar to Prognostic value of interim FDG-PET in DLBCL (20)
management of advanced cervical cancer [Autosaved].pptx
management of advanced cervical cancer [Autosaved].pptx
MON 2011 - Slide 24 - R.A. Stahel - NSCLC systemic therapy
MON 2011 - Slide 24 - R.A. Stahel - NSCLC systemic therapy
Precision Radiotherapy: Tailoring Treatment for Individualised Cancer Care.pptx
Precision Radiotherapy: Tailoring Treatment for Individualised Cancer Care.pptx
Oligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation Therapy
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
(March 29, 2023) Webinar: Evaluating Intracerebral Injections of Radiation Na...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Recently uploaded
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Top 10 Best Ayurvedic Kidney Stone Syrups in India
we have mentioned the best 10 ayurvedic Kidney Stone Syrups. You can check all these products and choose the best one for yourself.
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeProf. Marcus Renato de Carvalho
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxMGM SCHOOL/COLLEGE OF NURSING
Identification and nursing management of congenital malformations How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
STIs may cause PID. For the both disease, herbal medicine Fuyan Pill can be a solution.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...chandankumarsmartiso
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun Women Seeking Service
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Recently uploaded (20)
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Prognostic value of interim FDG-PET in DLBCL
- 1. !"# Prognostic value of interim FDG-PET in DLBCL
- 3. 背景：DLBCL的治疗现状 J Hematol Oncol.2020 Dec 14;13(1):175
- 4. Nat Rev Clin Oncol. 2017,10:631-645 背景：how to improve? 动态危险分层
- 7. 1. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. 2. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. 3. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. 4. Interobserver Agreement of Interim and End-of-Treatment 18 F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials.(HOVON Imaging Working Group) 5. Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma? iPET在DLBCL意义的随机对照临床研究（部分）
- 8. ü iPET Scans in DLBCL : Is It Ready for Prime Time? Clin Lymphoma Myeloma Leuk.2016;16(12):655-661 ü Δ SUVmax for interim PET in DLBCL: old is new Blood. 2020;135(25):2202-2203 ü iPET-driven strategy in DLBCL :do we trust the driver? Blood.2017;129(23):3059-3070 ü The role of PET in the first-line treatment of in DLBCL Lancet Haematol.2021;8(1):e80-e93 ü Interim PET in lymphoma: from Deauville to Peking criteria. On the road, again… Leuk Lymphoma.2018;59(3):523-525 iPET在DLBCL意义:专家的疑虑
- 10. 文献背景 文献解读 文献讨论
- 11. Prognostic value of interim FDG-PET in DLBCL -Results from the CALGB 50303 Clinical Trial Blood.2020;135(25):2224-2234.
- 12. • to identify biomarkers of response by FDG-PET • to evaluate the use of ΔSUVmax in defining response 研究目的
- 13. 流程图
- 14. 入组人群特征
- 15. 基线SUVmax分布 • median SUVmax :24.3 • Range:5.9-77
- 16. “Low” = 1 / 2 / 3, “High” = 4 / 5 结果：采用DS方法评判iPET 结果 PFS OS
- 18. 结果：采用ΔSUVmax评判iPET 结果 PFS OS ü 2yr PFS：62.5% (95% CI: 42.8%– 91.4%) vs. 85.3% (95% CI: 79.4%–91.6%) ü 2yr OS： 68.8% (95% CI: 49.4%–95.7%) vs. 93.8% (95% CI: 89.8%–98.1%)
- 19. 结论： ü In this phase 3 prospective clinical trial, ΔSUV on iPET predicted OS in large cell lymphoma ü ΔSUV may be an imaging biomarker that can help guide clinical trials using PET response-adapted therapy
- 20. iPET-CT Guided Therapy of Aggressive Non-Hodgkin Lymphomas -Results from the PETAL Clinical Trial J Clin Oncol.2018 Jul 10;36(20):2024-2034
- 21. PETAL 研究： iPET-CT驱动的治疗策略 J Clin Oncol.2018 Jul 10;36(20):2024-2034
- 22. 入组人群特征
- 23. iPET-CT 结果判定：采用DS方法 EFS OS PETAL 研究： iPET-CT 结果对预后的影响 ü 2yr EFS：65.9% vs. 75.0% ü 2yr OS： 80.8% vs. 88.1%
- 24. PETAL 研究： iPET-CT 结果对预后的影响 iPET-CT 结果判定：采用ΔSUVmax方法 EFS OS ü 2yr EFS：36.7% vs. 75.6% ü 2yr OS： 59.3% vs. 88.2%
- 25. ROC曲线对两种判读方法的比较
- 26. J Clin Oncol.2018 Jul 10;36(20):2024-2034 PETAL 研究： iPET-CT 结果对预后的影响 ü采用ΔSUVmax方法判断iPET-CT 结果优于DS方法 üiPET-CT结果可以预测预后
- 27. J Nucl Med.2021 Jan;62(1):37-42 iPET evaluation in DLBCL employing published recommendations - Comparison of the Deauville 5-point scale and the ΔSUVmax method
- 28. Key points
- 29. J Clin Oncol.2015;33(23):2523-9 Predictive Value of iPET-CT in Patients With DLBCL Treated With R-CHOP-14 -Results from the SAKK 38/07 Clinical Trial
- 30. 流程图 R-CHOP-14
- 31. 结果：采用DS方法评判iPET 结果 ü 2yr EFS：41.4% vs. 75.9% ü 2yr OS： 93.9% vs. 84.0%
- 32. 结果：采用ΔSUVmax评判iPET 结果 ü 2yr EFS：42.1% vs. 61.2% (p=NS) ü 2yr OS： 73.7% vs. 91.3%
- 33. iPET-CT in DLBCL predicts CR but has limited value in identifying patients with poor outcome -final result of a UK National Cancer Research Institute prospective study Br J Haematol.2021 Feb;192(3):504-513
- 34. 文献背景 文献解读 文献讨论
- 35. Prognostic value of iPET in DLBCL？ ü结果异质性的原因？ ü 疾病的异质性？方法抑制性？
- 36. Eur J Nucl Med Mol Imaging. 2013;40(9):1312-1320. 既往研究的结果 一项国际多中心回顾研究 • 评价iPET对DLBCL预后的意义 • 采用DS评分法与ΔSUVmax方法
- 37. Eur J Nucl Med Mol Imaging. 2013;40(9):1312-1320. 既往研究的结果 一项国际多中心回顾研究 • 评价iPET对DLBCL预后的意义 • 采用DS评分法与ΔSUVmax方法
- 38. Prognostic value of iPET in DLBCL？ üiPET 的价值：依然在路上？